The impact ofmissing data on the results of a schizophrenia study

Pharmaceutical Statistics

Volumn 14, Issue 1, 2015, Pages 4-10

  Rybin, Denis ^a,b   Doros, Gheorghe ^a,b   Rosenheck, Robert ^c,d   Lew, Robert ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c Education and Clinical Center   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bayesian analysis; Missing data; Pattern mixture; Sensitivity analysis

Indexed keywords

RISPERIDONE; NEUROLEPTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BAYES THEOREM; DATA ANALYSIS; FOLLOW UP; HUMAN; MENTAL HEALTH; MISSING DATA; OUTCOME ASSESSMENT; PSYCHIATRIST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STANDARD; STATISTICAL MODEL; VALIDITY; PROCEDURES; STATISTICS; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; BAYES THEOREM; FOLLOW-UP STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; STATISTICS AS TOPIC;

EID: 84921628674     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1651     Document Type: Article

References (16)

1. Lieberman JA, Stroup S, McEvoy J, Swartz Marvin, Rosenheck R, Perkins D, Keefe RSE, Davis S, Davis CE, Hsiao J, Severe J, Lebowitz B. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (catie) schizophrenia trial. New England Journal ofMedicine 2005; 353(12):1209-1223.
2. Rosenheck RA, Perlick D, Bingham S, Liu-Mares, Collins J, Warren S, Leslie D. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 2003; 290:2693-2702.
3. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994; 151:825-835.
4. Tollefson GD, Beasley CM Jr, Tran PV. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154:457-465.
5. Rubin DB. Inference and missing data. Biometrika 1976; 63 (3): 581-592.
6. Daniels MJ, Hogan JW. Missing data in longitudinal studies. Chapman & Hall: CRC Monographs on Statistics & Applied Probability, 2008.
7. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine 2011; 364(9):842-851.
8. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13(2):261-276.
9. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984; 10(3):388-398.
10. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford: Oxford University Press: USA, 2002.
11. Heckman JJ. Sample selection bias as a specification error. Econometrica 1979; 47(1):153-161.
12. Roderick JA Little. Pattern-mixture models for multivariate incomplete data. Journal of the American Satistical Association 1993; 88(421):125-134.
13. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 1988; 44:175-188.
14. Molenberghs G, Michiels B, Kenward MG, Diggle PJ. Monotone missing data and pattern-mixture models. Statistica Neerlandica 1998; 52(2):153-161.
15. (U.S.) National Research Council. The prevention and treatment of missing data in clinical trials. National Academies Press:Washington, D.C., 2010.
16. Wang Chenguang, Daniels Michael J. A note on mar, identifying restrictions, model comparison, and sensitivity analysis in pattern mixture models with and without covariates for incomplete data. Biometrics 2011; 67:810-818.